Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

20 Apr 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-y As presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy ciltacabtagene autoleucel was safe and led to encouraging rates of clinical responses.

Clinical Editorial

Nature Medicine published a clinical update in Research Highlights on 20 Apr 2026. The item focuses on Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. Open the detail page to review the full original feed content.